I-Corps: Handheld fluorescence reader that provides quantitative, multiplexed detection of fluorescence signals

I-Corps项目的更广泛影响/商业潜力是改善住院后心力衰竭患者的护理。心力衰竭（HF）是导致医学发病率、死亡率和高医疗保健成本的重要原因。2012年，美国有100万人因心力衰竭住院。 最近出院的心力衰竭患者中约有25%在30天内再次入院，导致每年27亿美元的额外医疗费用负担。 所提出的技术将提供病情恶化的早期症状前警报，以便在最近出院的HF患者出现症状并可能再次住院之前进行主动药物治疗和/或其他治疗护理调整。这个I-Corps项目旨在改善监测，特别是在家中的自我监测，为心力衰竭影响的个人。该技术允许每天连续监测和跟踪NT-proBNP生物标志物水平以及肌钙蛋白、CysC和血清钠等其他分析物。沿着。智能手机连接的每日手指针刺血液测试将测量，跟踪和报告循环NT-proBNP和相关的心脏生物标志物水平给医疗保健提供者。拟议中的技术将使用荧光检测和微流体沿着智能连接的健康功能，以允许医疗保健提供者监测患者出院后的状态，提供恶化状况的早期症状前警报，以在重新治疗之前进行主动药物治疗和/或其他治疗护理调整，该奖项反映了NSF的法定使命，并通过使用基金会的智力价值进行评估，更广泛的影响审查标准。

The broader impact/commercial potential of this I-Corps project is an improvement in care for heart failure patients after hospitalization. Heart failure (HF) is a significant cause of medical morbidity, mortality, and high health care costs. In 2012, 1 million hospital stays were for heart failure in the United States. Approximately twenty-five percent of recently discharged heart failure patients are readmitted within 30 days, resulting in an additional healthcare cost burden of $2.7B per year. The proposed technology would provide an early pre-symptomatic alert of a worsening condition to enable proactive medication and/or other therapeutic care adjustments before recently discharged HF patients become symptomatic and are potentially re-hospitalized. This I-Corps project aims to improve monitoring, specifically self-monitoring in the home, for heart failure-impacted individuals. The technology allows for daily serial monitoring and tracking of NT-proBNP biomarker levels along with other analytes like Troponin, CysC, and Serum Sodium. A smartphone-connected, daily finger stick blood test would measure, track, and report circulating NT-proBNP and related cardiac biomarker levels to a healthcare provider. The proposed technology would use fluorescence detection and microfluidics along with smart-connected health features to allow healthcare providers to monitor patient status after discharge, providing an early pre-symptomatic alert of a worsening condition to enable proactive medication and/or other therapeutic care adjustments before re-hospitalization is required.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.